A biopharmaceutical company focused on the discovery, development and commercialization of novel drugs in the areas of infectious disease, oncology and inflammation.
| Current Price | $0.06 | Mkt Cap | $647,254.38 |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 0.00 |
| Prev. Close | $0.06 | Div. (Yield) | N/A (N/A) |
| Daily Range | $0.04 - $0.06 | Volume | 0 |
| 52-Wk Range | $0.03 - $2.85 | Avg. Daily Vol. | 0 |
| Subject | Recs | Author | Date |
|---|
The best Bull and Bear pitches based on recency and number of recommendations.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about ADLS.OB.
Recs
JohnnyLC
(99.80)
Submitted: 5/29/2008 8:32:04 PM :
Start Price:
$2.20
ADLS.OB Score:
-90.66
Phase III results for Cethromycin looks good. Company planning on NDA submits in 3Q of this year but need a partnership to cover the 10M cost owned to Abbott upon filing of NDA. Company is undervalued right now but it all comes down to how good of a partnership deal they can negotiate. PPS has dropped low enough for me to make a gamble.
Find the members with the highest scoring picks in ADLS.OB.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| JohnnyLC | 99.80 |
|
|
1Y | $2.20 | -97.27% | -6.62% | -90.66 | 2 Comments | |
| pennysplants | 99.46 | 6/19/2007 |
|
5Y | $3.27 | -98.17% | -7.47% | -90.69 | 0 Comment | |
| punchkey | 21.22 | 6/19/2007 |
|
1Y | $3.40 | -98.24% | -7.45% | -90.79 | 0 Comment | |
| GrabBagGuy | < 20 | 6/12/2007 |
|
1Y | $3.51 | -98.29% | -5.89% | -92.40 | 0 Comment | |
| ProfTech | 69.79 | 6/27/2007 |
|
3Y | $2.45 | -97.55% | -4.69% | -92.86 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
